Related Experiment Video
Updated: Oct 9, 2025
Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
Published on: April 28, 2014
Matcha Green Tea Exhibits Bactericidal Activity against Streptococcus pneumoniae and Inhibits Functional Pneumolysin
Karin Sasagawa1,2, Hisanori Domon1,3, Rina Sakagami1
1Division of Microbiology and Infectious Diseases, Niigata University Graduate School of Medical and Dental Science, Niigata 951-8514, Japan.
Abstract:
Streptococcus pneumoniae is a causative pathogen of several human infectious diseases including community-acquired pneumonia. Pneumolysin (PLY), a pore-forming toxin, plays an important role in the pathogenesis of pneumococcal pneumonia. In recent years, the use of traditional natural substances for prevention has drawn attention because of the increasing antibacterial drug resistance of S. pneumoniae. According to some studies, green tea exhibits antibacterial and antitoxin activities. The polyphenols, namely the catechins epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), and epicatechin (EC) are largely responsible for these activities. Although matcha green tea provides more polyphenols than green tea infusions, its relationship with pneumococcal pneumonia remains unclear. In this study, we found that treatment with 20 mg/mL matcha supernatant exhibited significant antibacterial activity against S. pneumoniae regardless of antimicrobial resistance. In addition, the matcha supernatant suppressed PLY-mediated hemolysis and cytolysis by inhibiting PLY oligomerization. Moreover, the matcha supernatant and catechins inhibited PLY-mediated neutrophil death and the release of neutrophil elastase. These findings suggest that matcha green tea reduces the virulence of S. pneumoniae in vitro and may be a promising agent for the treatment of pneumococcal infections.
Insights
Matcha green tea supernatant shows antibacterial activity against Streptococcus pneumoniae, inhibiting its virulence factor pneumolysin. This suggests matcha may help treat pneumococcal infections, even those resistant to antibiotics.
Area of Science:
- Microbiology
- Natural Product Chemistry
- Immunology
Background:
- Streptococcus pneumoniae causes pneumonia, with increasing antibiotic resistance necessitating novel treatments.
- Pneumolysin (PLY) is a key toxin in pneumococcal disease pathogenesis.
- Green tea polyphenols, like catechins, possess antibacterial and antitoxin properties.
Purpose of the Study:
- To investigate the efficacy of matcha green tea against Streptococcus pneumoniae.
- To determine matcha's effect on pneumolysin (PLY) activity and host immune response.
Main Methods:
- Assessing matcha supernatant's antibacterial activity against S. pneumoniae.
- Evaluating matcha's inhibition of PLY-mediated hemolysis and cytolysis.
- Analyzing matcha's impact on PLY-induced neutrophil death and elastase release.
Main Results:
- Matcha supernatant demonstrated significant antibacterial activity against S. pneumoniae, irrespective of antimicrobial resistance.
- Matcha suppressed PLY-mediated hemolysis and cytolysis by inhibiting PLY oligomerization.
- Matcha and its catechins inhibited PLY-induced neutrophil death and neutrophil elastase release.
Conclusions:
- Matcha green tea exhibits antibacterial and anti-virulence properties against Streptococcus pneumoniae in vitro.
- Matcha may be a promising natural agent for managing pneumococcal infections, potentially by targeting pneumolysin.
- Further research into matcha's therapeutic potential for pneumococcal pneumonia is warranted.
More Related Videos
Related Concept Videos
01:13Special Staining Techniques
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia III: Complications and Assessment